NNovo Nordisk Read More A Critical Quarter Amid Price Wars and Regulatory Shifts2026-04-12 Novo Nordisk’s Q1 2026 report faces scrutiny over Ozempic/Wegovy price cuts in India and US tariffs, balanced by…